MarketCapExport financials
Encompass Health Corporation (EHC)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Encompass Health Corporation Financial Ratios 2025-2007 | EHC
Brief overview of Encompass Health Corporation's valuation and returns
This overview follows the five latest available observations from 2021 through 2025.
Market valuation is represented by P/E 19.04x (median 21.13x), EV/EBITDA 42.27x (median 11.56x), P/S 1.82x (median 1.62x). The combined ratio level is close to the company's five-year norm at a +1.6% deviation. No clear premium or discount is visible.
At the current P/E, inverse earnings yield is 5.3%, a useful bridge between price and business earnings.
End-period return metrics are ROE 23.2%, ROA 8%, ROCE 28.6%. Overall capital returns are high. The business uses resources efficiently and provides strong fundamental support for its valuation.
The cash cycle accelerated by 18.6 days to 18.7 days. Less capital is tied up in operations.
Overall picture
Encompass Health Corporation's valuation and business quality look relatively balanced, with no pronounced distortion in either direction.
Annual Financial Ratios Encompass Health Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19.0 | 21.8 | 21.1 | 22.1 | 15.8 | 27.3 | 21.1 | 22.3 | 19.5 | 13.9 | 17.5 | 17.2 | 8.5 | 12.2 | 8.7 | 1.6 | 9.2 | 4.9 | - | |
P/S |
1.8 | 1.8 | 1.5 | 1.4 | 1.6 | 2.2 | 1.6 | 1.5 | 1.3 | 0.9 | 1.0 | 1.6 | 1.2 | 1.1 | 0.9 | - | - | - | - |
EPS |
5.6 | 4.5 | 3.5 | 2.7 | 4.2 | 2.9 | 3.6 | 3.0 | 2.9 | 2.8 | 2.0 | 2.5 | 2.6 | 1.7 | 1.9 | 9.4 | 0.8 | 2.7 | - |
EV (Enterprise Value) |
14.5 B | 13.5 B | 11.2 B | 9.73 B | 10.9 B | 12 B | 11.9 B | 10.1 B | 8.41 B | 7.15 B | 6.96 B | 6.46 B | 4.67 B | 3.8 B | 3.86 B | 3.36 B | 2.98 B | 1.21 B | - |
EBITDA per Share |
3.26 | 3 | 2.75 | 3.99 | 3.52 | 3.77 | 9.3 | 8.47 | 8.89 | 9.22 | 7.68 | 6.63 | 6.55 | 5.28 | 8.08 | 0.79 | 0.76 | 0.99 | - |
EV/EBITDA |
44.3 | 45.2 | 40.8 | 24.6 | 31.4 | 32.4 | 11.6 | 10.8 | 9.0 | 7.8 | 9.2 | 10.2 | 7.3 | 6.8 | 4.0 | 45.9 | 44.1 | 14.6 | - |
PEG |
-14.43 | -1.46 | -1.43 | -2.31 | -1.22 | -3.6 | 0.94 | 2.44 | -13.49 | 0.37 | -0.98 | -0.52 | 0.1 | -0.97 | -0.12 | - | - | - | - |
P/B |
3.3 | 3.5 | 3.2 | 3.2 | 2.7 | 3.9 | 4.5 | 4.2 | 3.5 | 3.7 | 4.1 | 5.4 | 4.9 | 3.0 | 9.0 | 3.7 | -1.7 | - | - |
P/CF |
- | - | - | 8.5 | 9.1 | 11.0 | 32.7 | 13.3 | 12.1 | 8.5 | 9.7 | 14.9 | 10.9 | 8.9 | 7.8 | 4.3 | 2.1 | 5.4 | - |
ROE % |
23.22 | 22.05 | 21.37 | 20.68 | 21.57 | 17.90 | 21.19 | 18.77 | 17.99 | 26.66 | 23.50 | 31.15 | 57.59 | 24.79 | 103.52 | -1055.16 | -10.56 | -23.22 | - |
ROA % |
7.99 | 6.97 | 5.77 | 4.81 | 6.00 | 4.41 | 5.90 | 5.65 | 5.24 | 5.29 | 3.98 | 6.51 | 12.77 | 7.63 | 9.19 | 37.90 | 5.64 | - | - |
ROCE % |
- | - | - | 3.37 | 2.28 | 3.17 | 12.92 | 13.98 | 14.84 | 15.42 | 13.08 | 15.35 | 21.70 | 19.64 | 34.46 | - | - | - | - |
Current Ratio |
1.9 | 1.8 | 1.6 | 1.5 | 1.5 | 1.5 | 1.0 | 1.0 | 1.4 | 1.4 | 1.4 | 1.9 | 1.9 | 2.1 | 1.2 | 1.2 | 0.8 | - | - |
DSO |
39.2 | 42.9 | 47.2 | 50.5 | 58.6 | 69.3 | 40.1 | 39.9 | 44.0 | 44.4 | 48.1 | 49.7 | 42.5 | 42.6 | 40.1 | - | - | - | - |
DPO |
20.5 | 21.5 | 21.3 | 20.4 | 21.4 | 20.1 | 205.7 | 207.0 | 191.7 | 178.1 | 174.7 | 174.2 | 214.4 | 161.5 | - | 18.8 | - | - | - |
Operating Cycle |
- | - | - | - | - | - | 40.1 | 39.9 | 44.0 | 44.4 | 48.1 | 49.7 | 42.5 | 42.6 | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | -165.5 | -167.1 | -147.7 | -133.6 | -126.6 | -124.5 | -171.8 | -118.8 | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Financial Ratios Encompass Health Corporation
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q4 | 2010-Q3 | 2010-Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
1.53 | 1.56 | 1.8 | 1.4399999999999995 | 1.26 | 1.42 | 1.5 | 1.1999999999999997 | 1.09 | 1.14 | 1.13 | 0.9499999999999997 | 0.86 | 0.92 | 0.89 | 0.91 | 0.64 | 0.38 | 0.65 | 0.69 | 0.76 | 0.79 | 0.77 | 0.87 | 0.78 | 0.34 | 0.88 | 0.69 | 0.99 | 0.93 | 1.05 | 0.27 | 0.9 | 0.93 | 0.86 | 0.77 | 0.67 | 0.7 | 0.75 | 0.73 | 0.69 | 0.7 | 0.65 | 0.51 | 0.56 | 0.7 | 0.65 | 0.43 | 0.56 | 0.89 | 0.51 | -0.31 | 0.61 | 1.82 | 0.48 | 0.41 | 0.44 | 0.38 | 0.39 | 0.5 | 0.17 | 0.14 | 0.58 | 8.31 | 0.24 | 0.4 |
EBITDA per Share |
0.97 | 0.91 | 0.88 | - | 0.82 | 0.79 | 0.79 | - | 0.78 | 0.73 | 0.7 | - | 0.68 | 0.73 | 0.64 | - | 1.91 | 1.91 | 1.91 | - | 1.99 | 2.12 | 2.08 | 0.2 | 2.15 | 1.48 | 2.22 | -393 | 2.11 | 2.09 | 2.23 | - | 2.1 | 2.11 | 2 | 40.6 | 1.96 | 2.07 | 2.17 | -728 | 2.15 | 2.16 | 2.08 | 175 | 1.71 | 2.16 | 2.08 | - | 0.32 | 0.3 | 0.3 | 87 | 0.28 | 0.27 | 0.24 | - | 0.22 | 0.21 | 0.21 | -0.43 | 0.21 | 0.21 | 0.21 | - | 0.2 | 0.19 |
ROE % |
19.17 | 18.93 | 19.09 | 18.47 | 18.25 | 18.24 | 18.14 | 17.62 | 17.18 | 17.10 | 17.03 | 16.82 | 19.40 | 18.09 | 15.53 | 14.57 | 13.05 | 14.81 | 19.40 | 22.34 | 23.10 | 23.98 | 20.09 | 19.64 | 19.29 | 21.16 | 25.53 | 27.22 | 24.96 | 24.89 | 25.62 | 25.34 | 29.53 | 28.65 | 26.92 | 28.08 | 29.83 | 30.39 | 32.89 | 32.16 | 31.74 | 31.40 | 30.26 | 29.42 | 30.11 | 31.87 | 39.19 | 41.51 | 45.92 | 49.62 | 75.52 | 86.57 | 87.57 | 87.34 | 60.53 | 55.98 | 72.38 | 94.00 | 96.16 | 181.69 | -28060.12 | -28096.32 | -28116.82 | -28210.71 | -2.93 | -4.55 |
ROA % |
8.74 | 8.60 | 8.63 | 8.26 | 8.04 | 7.87 | 7.55 | 7.07 | 6.66 | 6.41 | 6.19 | 5.91 | 6.57 | 5.97 | 5.11 | 4.85 | 4.45 | 5.11 | 6.57 | 7.34 | 7.39 | 7.42 | 6.02 | 5.76 | 5.51 | 5.87 | 7.03 | 7.50 | 6.94 | 7.20 | 7.52 | 7.41 | 8.57 | 8.18 | 7.60 | 7.26 | 6.93 | 6.52 | 6.22 | 5.66 | 5.34 | 5.20 | 5.21 | 5.23 | 5.50 | 6.04 | 7.86 | 8.38 | 9.21 | 9.53 | 12.71 | 12.84 | 12.75 | 12.38 | 7.78 | 7.50 | 7.81 | 8.35 | 7.25 | 8.58 | 39.13 | 38.31 | 39.99 | 33.30 | 1.41 | 2.32 |
ROCE % |
- | 7.73 | 7.73 | - | 7.73 | 7.73 | 7.73 | - | 7.73 | 7.73 | 7.73 | - | 7.73 | 7.73 | 7.73 | 9.87 | 8.96 | 8.73 | 9.19 | 9.56 | 10.40 | 10.57 | 9.50 | 9.87 | 9.68 | 10.10 | 11.87 | 12.66 | 12.11 | 12.76 | 13.22 | 13.16 | 14.47 | 14.33 | 14.05 | 14.05 | 14.13 | 14.30 | 31.29 | 47.26 | 47.02 | 46.60 | 29.90 | 13.87 | 3.25 | 3.71 | 3.56 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
1.9 | 1.9 | 1.9 | 1.9 | 1.9 | 1.8 | 1.8 | 1.8 | 1.7 | 1.7 | 1.6 | 1.6 | 1.6 | 1.5 | 1.5 | 1.5 | 1.5 | 1.6 | 1.6 | 1.5 | 1.5 | 1.5 | 1.5 | 1.4 | 1.4 | 1.4 | 1.4 | 1.5 | 1.4 | 1.5 | 1.5 | 1.5 | 1.6 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.3 | 1.3 | 1.3 | 1.3 | 1.3 | 1.2 | 1.3 | 1.3 | 1.2 | 1.3 | 1.3 | 1.4 | 1.3 | 1.3 | 1.4 | 1.4 | 1.3 | 1.4 | 1.4 | 1.4 | 1.4 | 1.4 | 1.3 | 1.3 | 1.2 | 1.2 | 0.8 | 0.8 |
DSO |
39.7 | 38.9 | 19.6 | 18.2 | 37.8 | 38.7 | 19.7 | 18.9 | 39.4 | 42.4 | 21.9 | 20.0 | 40.4 | 40.2 | 20.7 | 20.5 | 48.5 | 57.6 | 30.0 | 28.5 | 57.1 | 57.4 | 30.6 | 22.7 | 44.6 | 46.6 | 21.3 | 20.2 | 39.8 | 40.1 | 20.6 | 19.4 | 39.1 | 39.3 | 20.8 | 20.5 | 40.4 | 40.8 | 21.4 | - | 15749.8 | 16873.7 | 8573.7 | - | 14666.5 | 16911.0 | 12712.3 | - | 12820.6 | 9563.7 | 3025.0 | - | 12024.5 | 7465.9 | 4472.8 | - | 6818.9 | 7207.3 | 3535.2 | - | 6358.1 | 6468.8 | 4573.4 | - | - | - |
DPO |
24.6 | 23.7 | 21.3 | 18.0 | 18.2 | 19.8 | 19.8 | 20.6 | 20.9 | 21.5 | 21.6 | 22.6 | 22.2 | 21.3 | 19.9 | 19.8 | 20.5 | 22.2 | 21.9 | 22.6 | 25.0 | 17.3 | 15.8 | -116.2 | 14.6 | 13.4 | 12.9 | 13.4 | 13.6 | 13.9 | 13.6 | 13.1 | 13.2 | 13.3 | 12.9 | 13.2 | 13.4 | 12.7 | 11.8 | 12.0 | 12.5 | 12.8 | 12.2 | 12.4 | 14.5 | 12.2 | 10.9 | 16.4 | 17.4 | 16.7 | 17.6 | 19.5 | 18.9 | 19.8 | 17.7 | 16.5 | 19.4 | 20.0 | 17.3 | 16.5 | 16.9 | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 16873.7 | 18077.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 16860.8 | 18064.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Multiples are an important financial analysis tool for the company Encompass Health Corporation, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
USA
Russia
Germany
Britain
China
